The overarching question imparting urgency to this exploration is: Can U.S.-Russian contention in cyberspace cause the two nuclear superpowers to stumble into war? In considering this question we were constantly reminded of recent comments by a prominent U.S. arms control expert: At least as dangerous as the risk of an actual cyberattack, he observed, is cyber operations’ “blurring of the line between peace and war.” Or, as Nye wrote, “in the cyber realm, the difference between a weapon and a non-weapon may come down to a single line of code, or simply the intent of a computer program’s user.”
Biography
Hillel Bachrach is a dynamic executive entrepreneur, with more than 40 years of hands-on experience managing and directing all aspects of the commercial global introduction of new, innovative, and revolutionary lifescience technologies. After a successful career as an entrepreneur, starting and exiting, IPO’s, Strategic & Sponsors’ buyouts, currently, Mr. Bachrach is the managing partner of 20/20 HealthCare Partners, LLC, a global investment entity he founded in 2005. As active investors, 20/20 HCP provides equity financing and BOD/Advisory support for promising growth businesses as well as for public offerings, buyouts or re-capitalizations of companies specializing in med-tech, diagnostic imaging hardware and software, HCIT and lately advanced Bio-Tech & AI technologies. In 2006, 20/20 HCP acquired a majority ownership in Viztek, a provider of Digital Radiography hardware and software solutions, where Mr. Bachrach served as executive chairman. In 2015, Viztek was acquired by Konica Minolta, a Japanese conglomerate. Mr. Bachrach also led various funding rounds for Corindus Vascular Robotics, (CVRS), and served on its Board of Directors from 2006 to 2017 during and post it becoming a publicly traded company. In addition, Mr. Bachrach served as president of Odin Medical Technologies, Inc., and helped found UltraSPECT, Ltd., the leader in providing sophisticated dose and procedure time reduction software solutions for nuclear medicine procedures. Other recent 20/20 HCP investments include Q Urological, a leader in the specialty urology marketplace, and VR Health, a provider of VR technology for the rehab/physical therapy market and Varinatyx, the only CLIA CAP approved labless-lab for whole Genome Sequencing Analysis. Mr. Bachrach serves on Variantyx BOD. In 2015, 20/20 HCP joined with Polaris Venture Fund in funding a promising biotech delivery company, SQZ Biotechnology, named one of the Fierce 15 biotech companies that year. 20/20 HCP was also instrumental in introducing Roche Pharma to SQZ for the signing of a $500MM collaboration agreement. In 2018 Roche extended its collaboration with SQZ to the tune of $1.125B. In 2017 20/20 HCP led the founding round of another Dr. Robert Langer Biotech technology, Verseau Therapeutics, specializes in extending the therapeutic reach of Immuno-Oncology therapy by targeting the macrophages impact on the innate immune system.
During the last few years Mr. Bachrach has divested his activities to include two new avenues, new media and lifestyle. On the media side, he co-led various investment rounds in Zixi, a leading enabler of flawless broadcast quality HDTV over the Internet. Velocomp, a developer of innovative and advanced cycling power meters, is Mr. Bachrach’s latest investment. He serves on the Boards of Directors of these two companies.
Mr. Bachrach was recently elected a Trustee at BIDMC. He and his wife, Liliana, are involved with and support the Boston Symphony Orchestra, the Whitehead Institute, Harvard Kennedy School’s Belfer Center for Science and International Affairs, MIT Deshpande Center for Technological Innovation, and Community Servings, among others.
Mr. Bachrach received a B.S in electrical engineering from Technion Israeli Institute of Technology and an M.B.A. from the Kellogg Graduate School of Management. The Bachrachs live in Boston’s Back Bay and have a son, Ilan, and a daughter, Ronny, who serves on the BIDMC Board of Overseers.
Last Updated: